AstraZeneca, Lilly and Bayer unveil new strategies at ESMO 2026 in Madrid
read at Endpoints ↗Neutral
At the European Society for Medical Oncology (ESMO) congress in Madrid, nearly 40,000 delegates gathered for the five-day meeting.
AstraZeneca said it is evaluating the use of its immunotherapy Keytruda to compete directly with Merck's Padcev in the relevant indication.
Eli Lilly presented an antibody-drug conjugate that it intends to position against the recently approved Elahere, while Bayer highlighted plans to test its prostate-cancer drug Nubeqa in earlier-stage disease.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer”
read at Endpoints ↗95 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that